MedPath

A randomized, double blind, multi-center, active drug controlled,phase III clinical trial to compare the safety and efficacy of BOTULAX® versus BOTOX® in treatment of post stroke upper limb spasticity.

Not Applicable
Completed
Conditions
Diseases of the musculo-skeletal system and connective tissue
Registration Number
KCT0001188
Lead Sponsor
Hugel
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
All
Target Recruitment
186
Inclusion Criteria

1. Male or female subjects no younger than 20 years of age.
2. Patients diagnosed with stroke =6 weeks prior to enrollment in current study
3. Focal spasticity score = 2 points at wrist flexor and = 1 point at one or more of the following muscles: elbow flexor and/or finger flexor (scores measured on the MAS (0 to 4))
4. A minimum of grade 2 in the targeted functional disability item (i.e., hygiene, dressing, upper-limb position sense, or pain) on the Disability Assessment Scale (0 to 3)
5. Voluntary informed consent signed by patient or patient’s legal guardian after objective, methods, and efficacy of clinical study have been explained

Exclusion Criteria

1. Subjects who have a history of Neuromuscular Junction Disorders (Ex,Myasthenia Graris,Lambert-Eaton myasthenic syndrome, Congenital myasthenic syndrome)
2. Patients with significant atrophy of the muscle in the target limb
3. Patients with fixed joint/muscle contracture* in the target limb
* Defined as inability to passively move the joints
4. Prior (within 6 months of administration of study drug) or planned (during study period) treatment with phenol/alcohol injection (chemodenervation) in the target limb
5. Prior (within 6 months of administration of study drug) or planned (during study period) tendon lengthening surgery in the target limb

Study & Design

Study Type
Interventional Study
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Improvement of Modified Ashworth Scale (MAS) scores of wrist flexor evaluated by the investigator in weeks 4 from the Investigatioal Product injection
Secondary Outcome Measures
NameTimeMethod
Improvement of Modified Ashworth Scale (MAS) scores of elbow flexor, finger flexor, thumb flexor evaluated by the investigator in weeks 4 from the Investigatioal Product injection;Improvement of Modified Ashworth Scale (MAS) scores of wrist flexor, elbow flexor, finger flexor, thumb flexor evaluated by the investigator in weeks 8,12 from the Investigatioal Product injection;Laboratory Tests;Vital Signs (Blood pressure, pulse and temperature)
© Copyright 2025. All Rights Reserved by MedPath